Andre Larente from DIAGNOS to Host InvestorTalk (04.24.2024)

written by InvestorNews | April 24, 2024
InvestorNews is hosting an InvestorTalk this morning with <u>André Larente</u>, CEO, President, and Director from <u>DIAGNOS Inc.</u> (TSXV: ADK | OTCQB: DGNOF) at 9 AM EST. To participate in the InvestorTalk, please <u>click here</u>

DIAGNOS has $\frac{76,648,586}{}$ shares outstanding and a market cap of CAD\$22,994,576.

In preparing for this morning's InvestorTalk here are the latest news releases for your review:


- April 16, 2024 DIAGNOS to expedite application for Medical Device License to Health Canada and US FDA related to its 4 new analysis modules, and is planning ISO 27001 certification — <u>click here</u>
- April 9, 2024 DIAGNOS Inc. to Present at the Technology Hybrid Investor Conference April 11th click here
- April 2, 2024 DIAGNOS Welcomes Dr. Philippe Couillard to its Board of Directors click here

5-Data Points from the most recent news release:

- 1. **Approval Process**: Diagnos Inc. is working to obtain Health Canada and U.S. FDA approvals for four additional AI analysis modules, with plans to commercialize these during Q3 2024.
- 2. Module Functions: The new AI modules are designed to assist healthcare professionals in identifying abnormal Optical Coherence Tomography (OCT) retinal images and in

- grading Fundus images for signs of AMD (Age-Related Macular Degeneration), DR (Diabetic Retinopathy), and HR (Hypertensive Retinopathy).
- 3. Impact on Revenue and Distribution: The modernization of Diagnos' Health Canada license is seen as essential for distribution partnerships, including with Essilor Luxottica for the Canadian market, and for potential expansion into the U.S. market. This expansion is expected to accelerate revenue growth for Diagnos.
- 4. **ISO 27001 Certification**: Diagnos is also progressing towards obtaining ISO 27001 Cyber Security certification, which is a requirement from current and prospective customers to enhance data security.
- 5. Company Background and AI Platform: Diagnos is a publicly traded company on the TSX Venture Exchange and the OTCQB. It specializes in early detection of critical health issues using its FLAIRE AI platform, which supports the development and application of AI technologies such as CARA (Computer Assisted Retina Analysis) for enhanced retinal image analysis.

(04.24.2024 - Premarket, <u>Source</u>)



The last InvestorNews Interview was on December 14, 2023, and

was titled: <u>Andre Larente from DIAGNOS on Deal with World's</u>
<u>Largest Eyecare Retailer EssilorLuxottica</u>